Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients

Tao Wang,Xiao-Jie Lu,Jia-Chang Chi,Min Ding,Yuan Zhang,Xiao-Yin Tang,Ping Li,Li Zhang,Xiao-Yu Zhang,Bo Zhai
DOI: https://doi.org/10.1038/srep32728
IF: 4.6
2016-01-01
Scientific Reports
Abstract:This retrospective study aimed at evaluating the long-term outcomes and prognostic factors of microwave ablation (MWA) as a first-line treatment for hepatocellular carcinoma (HCC). 221 consecutive patients receiving MWA in our center between October 11, 2010 and December 31, 2013 were enrolled. Technique effectiveness was evaluated one month post-ablation. Initial complete ablation (CA1 st ) was gained in 201 (90.95%) patients, secondary CA (CA2 nd ) in 8 (3.62%) patients and the remaining 12 (5.43%) patients suffered from incomplete ablation (IA2 nd ) after two sessions of MWA. Patients with tumor size >5 cm were less likely to gain CA1 st . Procedure-related complications were recorded and no procedure-related death occurred. 22 (10.4%) complications occurred with 8 (3.8%) being major ones. Tumor characteristics (size, number, location) do not significantly influence complication rates. After a median follow-up of 41.0 (ranging 25.0–63.5) months, the median RFS and OS was 14.0 months (95% CI: 9.254–18.746) and 41.0 months (95% CI: 33.741–48.259) respectively. Multivariate analysis identified two significant prognosticators (levels of alpha fetal protein [AFP] and gamma-glutamyl transpeptidase [GGT]) of RFS and five significant prognosticators (tumor number, tumor size, AFP, GGT and recurrence type) of OS. In conclusion, MWA provides high technique effectiveness rate and is well tolerated in patients with HCC as a first-line treatment.
What problem does this paper attempt to address?